A Phase I, Double-Blind, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs NTM 1633 (Primary)
- Indications Botulism
- Focus Adverse reactions; First in man
- 03 Jul 2019 Status changed from active, no longer recruiting to completed.
- 21 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Sep 2018 Status changed from not yet recruiting to recruiting.